|
|
Article: Clinic Roundup.
- Article from:
- BIOWORLD Today
- Article date:
- November 3, 2009
CopyrightCOPYRIGHT 2009 A Thomson Healthcare Company. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
o DeCode Genetics Inc., of Reykjavik, Iceland, began enrolling patients in its Phase I development program for DG051, the company's follow-on compound for preventing heart attacks. The study will examine DG051, a small-molecule inhibitor of leukotriene A4 hydrolase. The compound is similar to DG031, its lead compound for the preventing heart attacks now in a Phase III trial.
o Depomed Inc., of Menlo Park, Calif., completed a Phase I trial to evaluate the delivery and absorption of a compound used to treat gastroesophageal reflux disease. The trial was conducted in healthy volunteers to evaluate specific pharmacokinetic and absorption behavior of the drug compound ...